New combo therapy targets liver metastases in melanoma patients
NCT ID NCT07281924
First seen Jan 10, 2026 · Last updated May 05, 2026 · Updated 17 times
Summary
This study tests whether combining a liver-directed chemotherapy (HEPZATO KIT) with two immunotherapy drugs (nivolumab and relatlimab, together called Opdualag) is safe and effective for people with metastatic melanoma that has spread to the liver. About 15 participants who have not had prior systemic treatment will receive the combination. The goal is to see if this approach works better than standard immunotherapy alone for liver metastases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Hospital and Clinics
RECRUITINGMadison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.